Its effectiveness in humans has been limited due to several potential causes: heterogeneous antigen expression leading to incomplete tumor eradication; limited persistence of TCR-T cells; tumor immune escape mechanism through downregulation of HLA-A molecules; or loss of tumor NY-ESO-1 expression [108,109]. This evidence concerns the gene HLA-A and neoplasm.